The global protein drugs market should reach $394.2 billion by 2026 from $265.0 billion in 2021 at a compound annual growth rate (CAGR) of 8.3% for the forecast period of 2021 to 2026.
The monoclonal antibodies segment of the global protein drugs market is expected to grow from $126.7 billion in 2021 to $208.6 billion in 2026 at a CAGR of 10.5% for the forecast period of 2021 to 2026.
The vaccines segment of the global protein drugs market is expected to grow from $35.4 billion in 2021 to $50.4 billion in 2026 at a CAGR of 7.3% for the forecast period of 2021 to 2026.
Report Scope
This report will focus on protein drugs, classification and manufacturing technologies. The protein drugs market can be classified into peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. This report focuses on six techniques for manufacturing protein therapeutics, including fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The report focuses on each market and its applications, regulatory environment, latest trends and developments, drivers, restraints and challenges affecting the market.
The report covers company profiles for all the major companies and also company share analysis. This report also covers market projections to 2026 and relevant patent analysis. By geography, the market has been segmented into the United States, Europe and emerging markets. Emerging markets include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. For market estimates, data has been provided for the year 2019, 2020 (as base year) and forecast through 2026.
The Report Includes
- 37 data tables and 28 additional tables
- An overview of the global markets and manufacturing technologies for protein drugs
- Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the current and future market potential and quantification of protein drugs market based on type, manufacturing process and region
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- A detailed description of protein drugs, their classification and six main manufacturing technologies and information on recombinant deoxyribonucleic acid (rDNA) technology
- Information on advancements in manufacturing technologies, new product launches of the industry and discussion on the effect of biosimilars entry to the protein drugs market
- Detailed analysis of the regulatory framework and policies and technological changes within the industry
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players of the industry, including AbbVie Inc., Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer Inc. and Sanofi S.A.
What is the estimated value of the Global Markets and Manufacturing Technologies for Protein Drugs?
What is the growth rate of the Global Markets and Manufacturing Technologies for Protein Drugs?
What is the forecasted size of the Global Markets and Manufacturing Technologies for Protein Drugs?
Who are the key companies in the Global Markets and Manufacturing Technologies for Protein Drugs?
| Report Attribute | Details |
|---|---|
| No. of Pages | 159 |
| Published | August 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 265 Billion |
| Forecasted Market Value ( USD | $ 394.2 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
Table of Contents
Samples
LOADING...
Executive Summary
Proteins, an important class of regulatory molecules, are the building blocks of the body. Protein therapeutics has become an important segment of the healthcare industry. Genetic engineering technology makes it possible to produce these protein molecules with modified features. Due to high specificity and low immunogenicity, protein therapeutics is widely used to treat various life-threatening diseases such as cancer, diabetes and multiple sclerosis.
Increasing R&D, sedentary lifestyles, increasing incidence of various diseases, and the increasing population of baby boomers drive this market.
Monoclonal antibodies are the largest segment in terms of revenue. The use of monoclonal antibodies has increased due to the increase in various chronic diseases. However, the market is facing competition from the entry of follow-on biologics. Insulin analogs, which are more efficient than recombinant insulin, are a contributing factor for the growth of the market. Vaccines are another growth segment in the biopharmaceutical industry. The COVID-19 pandemichas led to increasing public awareness toward vaccination. Government efforts to eradicate viral and bacterial infections are driving factors for the vaccine market. Improved manufacturing technologies have also fueled the vaccine market. Some key players in the protein drug market include F. Hoffmann-LaRoche Ltd., AbbVie Inc., Amgen Inc., Biogen Inc., Sanofi S.A., Novo Nordisk, GlaxoSmithKline, Merck & Co. and more.
The U.S. leads the protein therapeutics market. Follow-on-biologics and price pressures are the major threats for the market. A rapid increase in medical technologies, improved diagnosis of disease, and the expansion of healthcare in emerging markets are expected to positively impact the protein therapeutics market.
The global market was further segmented by manufacturing processes; protein therapeutics made through cell culture had the biggest share.
Companies Mentioned
- Abbvie Inc.
- Alexion Pharmaceuticals
- Amgen Inc.
- Apotex Inc.
- Bayer Pharmaceuticals
- Biogen
- Biomarin Pharmaceutical Inc.
- Biotest
- Bristol-Myers Squibb
- CSL Ltd.
- Eli Lilly
- F. Hoffmann-La Roche Ag
- Fresenius Kabi
- Glaxosmithkline
- Grifols S.A.
- Johnson & Johnson
- Merck & Co., Inc.
- Merck Kgaa
- Novartis Ag
- Novo Nordisk Ag
- Octapharma Ag
- Pfizer Inc.
- Sandoz
- Sanofi S.A.
- Seagen
- Takeda Pharmaceutical Co., Ltd.
- UCB Co.
